Natera, Inc. $NTRA Shares Acquired by Hsbc Holdings PLC

Hsbc Holdings PLC boosted its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 43.0% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 86,750 shares of the medical research company's stock after buying an additional 26,097 shares during the quarter. Hsbc Holdings PLC owned 0.06% of Natera worth $23,551,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of NTRA. Integrated Wealth Concepts LLC grew its stake in shares of Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company's stock worth $221,000 after purchasing an additional 96 shares during the last quarter. NewEdge Advisors LLC grew its position in Natera by 68.3% in the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company's stock worth $644,000 after buying an additional 1,847 shares during the last quarter. Focus Partners Wealth grew its position in Natera by 8.6% in the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company's stock worth $847,000 after buying an additional 474 shares during the last quarter. Sivia Capital Partners LLC bought a new position in shares of Natera in the second quarter valued at $298,000. Finally, WINTON GROUP Ltd bought a new position in shares of Natera in the second quarter valued at $558,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on NTRA. Wolfe Research assumed coverage on Natera in a report on Tuesday, June 2nd. They set an "outperform" rating and a $260.00 price objective on the stock. Royal Bank Of Canada raised shares of Natera from an "outperform" rating to a "buy" rating in a research report on Tuesday. UBS Group set a $260.00 price target on shares of Natera in a report on Wednesday, June 24th. BTIG Research raised their price objective on shares of Natera from $290.00 to $320.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Finally, Piper Sandler lifted their price objective on shares of Natera from $249.00 to $363.50 and gave the stock an "overweight" rating in a research report on Wednesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $322.50.

Natera Stock Performance

NTRA stock opened at $324.14 on Wednesday. The stock has a market cap of $46.72 billion, a P/E ratio of -238.34 and a beta of 1.54. The firm has a 50 day simple moving average of $294.79 and a 200 day simple moving average of $239.44. Natera, Inc. has a 52 week low of $157.43 and a 52 week high of $343.18.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. During the same period in the previous year, the firm posted ($0.74) earnings per share. The firm's revenue was up 37.7% on a year-over-year basis. Sell-side analysts predict that Natera, Inc. will post -1.02 EPS for the current year.

Insider Transactions at Natera

In other news, CEO Steven Chapman sold 1,698 shares of the firm's stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $320.99, for a total transaction of $545,041.02. Following the completion of the sale, the chief executive officer directly owned 98,199 shares of the company's stock, valued at $31,520,897.01. This trade represents a 1.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 15,160 shares of Natera stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $326.89, for a total value of $4,955,652.40. Following the sale, the insider owned 110,859 shares of the company's stock, valued at approximately $36,238,698.51. This represents a 12.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 71,206 shares of company stock worth $19,944,069 in the last ninety days. Company insiders own 5.05% of the company's stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.